

# Synaptotagmin-2 Controls Regulated Exocytosis but Not Other Secretory Responses of Mast Cells\*

Received for publication, January 2, 2009, and in revised form, April 1, 2009. Published, JBC Papers in Press, May 27, 2009, DOI 10.1074/jbc.M109.002550

Ernestina Melicoff<sup>‡</sup>, Leticia Sansores-Garcia<sup>‡</sup>, Alejandra Gomez<sup>§</sup>, Daniel C. Moreira<sup>§</sup>, Proleta Datta<sup>¶</sup>, Pratima Thakur<sup>¶</sup>, Youlia Petrova<sup>‡</sup>, Tanya Siddiqi<sup>‡</sup>, Jayasimha N. Murthy<sup>‡</sup>, Burton F. Dickey<sup>‡</sup>, Ruth Heidelberger<sup>¶</sup>, and Roberto Adachi<sup>‡1</sup>

From the <sup>‡</sup>Department of Pulmonary Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, the

<sup>§</sup>Medical School, Tecnológico de Monterrey, Monterrey, Nuevo Leon 64710, Mexico, and the <sup>¶</sup>Department of Neurobiology and Anatomy, The University of Texas Medical School at Houston, Houston, Texas 77030

Mast cell degranulation is a highly regulated, calcium-dependent process, which is important for the acute release of inflammatory mediators during the course of many pathological conditions. We previously found that Synaptotagmin-2, a calcium sensor in neuronal exocytosis, was expressed in a mast cell line. We postulated that this protein may be involved in the control of mast cell-regulated exocytosis, and we generated Synaptotagmin-2 knock-out mice to test our hypothesis. Mast cells from this mutant animal conferred an abnormally decreased passive cutaneous anaphylaxis reaction on mast cell-deficient mice that correlated with a specific defect in mast cell-regulated exocytosis, leaving constitutive exocytosis and nonexocytic mast cell effector responses intact. This defect was not secondary to abnormalities in the development, maturation, migration, morphology, synthesis, and storage of inflammatory mediators, or intracellular calcium transients of the mast cells. Unlike neurons, the lack of Synaptotagmin-2 in mast cells was not associated with increased spontaneous exocytosis.

Mast cells (MCs)<sup>2</sup> participate in adaptive and innate immune responses. Their secreted products play important roles in immunoglobulin E (IgE)-dependent inflammatory reactions such as allergic asthma and anaphylaxis (1) and are also involved in other forms of inflammation such as immune arthritis (2, 3) and innate immune responses to bacterial infections (4, 5). Upon activation, MCs exhibit three main secretory responses: release of granule contents (*i.e.* degranulation), secretion of prostaglandins and leukotrienes, and secretion of cytokines and growth factors (6). The exocytic release of pre-

formed mediators (*e.g.* histamine and proteases) stored in secretory granules is immediate and regulated at the step of fusion between the membrane of the granule and the plasma membrane. Thus, it is an example of regulated exocytosis, like neuronal synaptic neurotransmitter release and insulin secretion (7). Another early event is the release of metabolites of arachidonic acid (*e.g.* prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) and leukotriene C<sub>4</sub> (LTC<sub>4</sub>)). These eicosanoids cross the plasma membrane using transmembrane transporters (8), and their production is regulated by the activation of their synthetic enzymes (9). A late response after MC activation is the secretion of cytokines and growth factors (*e.g.* tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-4 (IL-4)). The gap in time of minutes to hours between stimulation and the secretion of these mediators is explained by the fact that regulation is at the transcriptional and post-transcriptional levels, with secretion occurring via constitutive exocytosis (10).

A common intracellular mediator linking the stimulation event to these three MC responses is calcium (Ca<sup>2+</sup>) that is released into the cytoplasm from intracellular stores and introduced from the extracellular environment via specialized channels. Increase in the cytoplasmic concentration of Ca<sup>2+</sup> ([Ca<sup>2+</sup>]<sub>i</sub>) is required for the activation of phospholipase A2 and other enzymes in the synthetic pathway of prostaglandins and leukotrienes, for the expression of cytokines and growth factors, and for the regulated exocytosis of MC secretory granules (11).

MC degranulation is a highly regulated process, and, like other exocytic events, it requires the participation of soluble NSF (N-ethylmaleimide-sensitive fusion protein) adaptor protein receptor (SNARE) proteins. These are present both on the cytoplasmic surfaces of secretory vesicles (v-SNAREs such as vesicle-associated membrane protein, VAMP) and of the plasma membrane (target or t-SNAREs such as Syntaxin and synaptosome-associated protein of 25 kDa, SNAP-25). Cognate v- and t-SNAREs form a highly stable quadruple  $\alpha$ -helix complex (core complex) apposing the vesicle and target membranes. According to the "zipper hypothesis" the coiling of this complex drives the fusion between these membranes, opening a fusion pore and releasing the vesicle contents into the extracellular space (12). This step is Ca<sup>2+</sup>-dependent and is under the control of multiple proteins such as Synaptotagmin (Syt) (13).

There are at least 15 Syts in mammals, and several of them mediate Ca<sup>2+</sup>-dependent exocytosis. All Syts have a short

\* This work was supported by Grant 0655003Y from the American Heart Association (to R. A.).

<sup>1</sup> To whom correspondence should be addressed: The University of Texas M. D. Anderson Cancer Center, 2121 Holcombe Blvd. 703D, Box 1100, Houston, TX 77030. Fax: 713-563-0411; E-mail: radachi@mdanderson.org.

<sup>2</sup> The abbreviations used are: MC, mast cell; BMMC, bone marrow-derived MC; [Ca<sup>2+</sup>]<sub>i</sub>, cytoplasmic Ca<sup>2+</sup> concentration; C<sub>m</sub>, plasma membrane capacitance;  $\Delta$ , change; DNP, 2,4-dinitrophenol; EM, electron microscopy; Fc $\epsilon$ R $\alpha$ ,  $\alpha$ -subunit of the high affinity receptor for IgE; FITC, fluorescein isothiocyanate; HSA, human serum albumin; IgE, immunoglobulin E; IL, interleukin; LTC<sub>4</sub>, leukotriene C<sub>4</sub>; NSF, N-ethylmaleimide-sensitive fusion protein; P16, postnatal day 16; PCA, passive cutaneous anaphylaxis; PGD<sub>2</sub>, prostaglandin D<sub>2</sub>; SCF, stem cell factor; SNAP-25, synaptosome-associated protein of 25 kDa; SNARE, soluble NSF adaptor protein receptor; Syt, Synaptotagmin; TNF- $\alpha$ , tumor necrosis factor  $\alpha$ ; VAMP, vesicle-associated membrane protein; W<sup>sh</sup>/W<sup>sh</sup>, MC-deficient B6.Cg-Kit<sup>W-sh</sup>/Kit<sup>W-sh</sup> mouse; GTP $\gamma$ S, guanosine 5'-3-O-(thio)triphosphate.

intravesicular N terminus, a transmembrane domain, a variable linker region, and two conserved C<sub>2</sub> domains (C<sub>2</sub>A and C<sub>2</sub>B) at their C terminus. The binding of Ca<sup>2+</sup> to the C<sub>2</sub> domains alters their electrostatic surface charge and mediates most of the Ca<sup>2+</sup>-dependent functions of Syt (13). The C<sub>2</sub>A domains of Syt1, -2, and -9 bind Ca<sup>2+</sup> with low affinity and high cooperativity. These Syts were first identified in neurons where they control fast, synchronous, Ca<sup>2+</sup>-dependent synaptic vesicle exocytosis. Syt1 mediates this form of exocytosis in forebrain neurons (14) and Syt9 in limbic and striatal neurons (15). Both of them also mediate rapid exocytosis of dense core granules in adrenal chromaffin cells. We showed that Syt2 functions as the Ca<sup>2+</sup> sensor for fast synchronous synaptic vesicle release in hind-brain neurons and at the neuromuscular junction and that deletion of Syt2 produces a severe neurologic phenotype that results in death during the third week of postnatal life (16, 17). These low Ca<sup>2+</sup> affinity Syts also inhibit spontaneous and slow asynchronous vesicle exocytosis in the neurons where they are expressed (14–17). We previously identified Syt2 as the major Syt isoform expressed in the RBL-2H3 MC line (18). Here we study the effects of Syt2 deficiency in MC secretion *in vivo*. We show that Syt2-null mice contain normal MCs in number and morphology in their peritoneal cavity and skin and that MCs can be generated from the bone marrow of these mutant mice. Although no defects were found in IgE-dependent generation and secretion of cytokines and eicosanoids, the MCs in our Syt2-null mice had a marked deficiency in the exocytosis of their preformed granule mediators.

## EXPERIMENTAL PROCEDURES

**Animals and Cells**—MC-deficient and Syt2 knock-out mice have been described (17, 19). We produced all experimental animals and littermate controls by heterozygous crossings of a Syt2<sup>+/-</sup> line that we backcrossed 13 times into C57BL/6. We harvested and purified peritoneal MCs as described (4). We harvested bone marrow from femurs of postnatal day 16 (P16) mice to generate bone marrow-derived MCs (BMMCs). Cells were grown in RPMI 1640 (with 1% fetal calf serum, 100 μM Hepes buffer pH 7.3, 1 mM sodium pyruvate, 1× nonessential amino acids, and 0.1% β-mercaptoethanol) supplemented with mIL-3 5 ng/ml and stem cell factor (SCF) 100 ng/ml for 6 weeks. We followed the viability of BMMCs by Trypan Blue exclusion, and their maturation and differentiation by flow cytometry using labeled antibodies against the α-subunit of the high affinity receptor for IgE (FcεRIα; eBioscience) and cKit/CD117 (BD Pharmingen).

**Immunohistochemistry and Immunoblotting**—Cytospins of peritoneal MCs were postfixed with cold acetone, blocked with 3% bovine serum albumin/0.4% Triton X-100, incubated first with rabbit anti-Syt2 antibody 1:500 (A320; Dr. T. C. Südhof, Stanford University School of Medicine, Stanford, CA) (17) for 16 h at 4 °C, then with peroxidase-conjugated antirabbit antibody (Jackson ImmunoResearch) for 2 h at room temperature, and finally with 3,3'-diaminobenzidine (DAB; Vector). We used the same antibody for the immunoblotting of peritoneal MC lysates resolved by SDS-PAGE and transferred to nitrocellulose membranes. GAPDH (glyceraldehyde-3-phosphate

dehydrogenase), detected with a specific antibody (Abcam), was used as a loading control.


**Microscopy**—We harvested and processed tissues, peritoneal lavage, and electron microscopy (EM) samples from P16 mice as described (4). In tissue sections, we stained MC secretory granules with fluorescein isothiocyanate (FITC)-avidin and nuclei with Hoechst (Invitrogen-Molecular Probes), and then counted nucleated MC profiles (FITC<sup>+</sup>/Hoechst<sup>+</sup>) in randomized sections. In ears, we used the autofluorescence of cartilage, epidermis, and muscle in the red channel to calculate the dermis area by subtracting the cartilage and muscle areas from the area between the two epidermal edges. We counted peritoneal MCs using a Neubauer chamber and cytopins (Wright-Giemsa). We obtained EM pictures of BMMCs and peritoneal MCs using an unbiased random sampling technique. We calculated the volume fraction and the surface density of the granules using the point counting method with a cycloid grid, and the profile area using a point grid (20).

**Secretion Assays**—For each experiment, we suspended 10<sup>6</sup> BMMCs in 1 ml of culture medium and sensitized them with anti-2,4-dinitrophenol (DNP) IgE 5 μg/ml for 3 h. After repeated washes, we stimulated them with 100 ng/ml of DNP-human serum albumin (DNP-HSA). We measured all products in supernatants before and after stimulation. We also measured β-hexosaminidase in cell lysates (10<sup>6</sup> BMMCs treated with 1 ml of 0.2% Triton X-100). After stimulation, we measured LTC<sub>4</sub> and PGD<sub>2</sub> at 30 min, β-hexosaminidase and histamine at 1 h, TNF-α at 6 h, and IL-4 at different time points. We used enzyme-linked immunosorbent assays (ELISA, Oxford Biomed Res) to measure all products except β-hexosaminidase activity, which was measured by colorimetry using as substrate 4-nitrophenyl N-acetyl-β-D-glucosaminide.

**MC Reconstitution and Passive Cutaneous Anaphylaxis (PCA)**—We used BMMCs derived from Syt2<sup>+/+</sup> or Syt2<sup>-/-</sup> P16 mice for reconstitution of both ears of MC-deficient B6.Cg-Kit<sup>W-sh/Kit</sup> mice. After 6 weeks in culture, 10<sup>5</sup> BMMCs were suspended in 25 μl of PBS and injected intradermally into each ear pinna. Six weeks later, we quantified the MCs in the ears of some animals by histology and then performed the PCA sensitization and challenge on the rest as described (4).

**Intracellular Ca<sup>2+</sup> Measurements**—Peritoneal MCs from P16 mice were sensitized with 3 μg/ml of anti-DNP IgE for 2 h, plated onto coverslips and incubated in 5 μM Fura 2-AM. Intracellular calcium of each individual MC was ratiometrically calculated (21, 22). The fluorescence of an unstimulated MC was measured for 60 s prior to the addition of DNP-HSA to a final concentration of 0.5 μg/ml.

**Electrophysiological Recordings**—Whole cell capacitance measurements of individual peritoneal MCs were made at room temperature using 5 to 6 MΩ sylgard-coated patch pipettes (21). The intracellular recording solution both defined the [Ca<sup>2+</sup>]<sub>i</sub> and stimulated exocytosis (23–25). It contained (mM) 135 potassium gluconate, 7 MgCl<sub>2</sub>, 3 KOH, 2.5 K<sub>2</sub>EGTA, 7.5 Ca-EGTA, 0.2 Na-ATP, 0.005 Li<sub>4</sub>GTPγS, and 0.1 bis-Fura 2, 10 HEPES (pH 7.2, 305 mOsm) (23), with a calculated free [Ca<sup>2+</sup>] of ~700 nM that was experimentally verified. The exter-




**FIGURE 1. Syt2 is expressed in mature MCs.** Peritoneal MCs purified from P16 *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice. **A**, immunoblot of cell lysates with anti-Syt2 antibody (αSyt2). GAPDH immunoreactivity was used as a loading control. **B**, immunohistochemistry of cytopins using the same antibody (bar, 4 μm). We demonstrated the presence of Syt2 in mature wild type MCs and the absence of Syt2 in *Syt2*<sup>-/-</sup> MCs.

nal recording solution contained (mM) 140 NaCl, 2.5 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 glucose, 10 HEPES (pH 7.2 and 310 mOsm).

## RESULTS AND DISCUSSION

**Syt2 Expression in MCs**—In previous studies, we showed that Syt2 is the main Syt isoform expressed in the RBL-2H3 MC line (18). Neurons from *Syt2*<sup>-/-</sup> mice have severe impairments in Ca<sup>2+</sup>-dependent-regulated exocytosis (16, 17), so we wondered if this low Ca<sup>2+</sup> affinity exocytic Syt may play a similar role in a non-neuronal cell, such as the MC, in which activation does not depend on Ca<sup>2+</sup> entry through voltage-gated channels in the plasma membrane. Our first step was to confirm expression of Syt2 in normal MCs using cells from our *Syt2*<sup>-/-</sup> mice as negative controls. Immunoblots of *Syt2*<sup>+/+</sup> MC lysates showed intense staining at ~80 kDa, whereas *Syt2*<sup>-/-</sup> MC lysates showed no immunoreactivity at this mobility (Fig. 1A), and we observed perigranular immunohistochemical staining for Syt2 only in *Syt2*<sup>+/+</sup> peritoneal MCs (Fig. 1B). Together, these results provide evidence of the expression of Syt2 in mature endogenous MCs.

**Syt2 Deficiency Impairs an MC-dependent Allergic Reaction**—PCA models the acute phase of an allergic reaction. In PCA, we measure the localized vasodilation and increased endothelial permeability induced by products secreted by skin-resident MCs (26). All animals we used are on a C57BL/6 genetic background. We initially found a decreased PCA response in *Syt2*<sup>-/-</sup> mice compared with *Syt2*<sup>+/+</sup> mice (not shown). A flaw in these pilot experiments was that altered responses of Syt2-deficient cells other than MCs (e.g. vascular smooth muscle relaxation and endothelial cell retraction) could also be responsible for the observed difference. To avoid this confounding factor and to guarantee that only the MCs in our model will be differentially deficient or sufficient in Syt2, we reconstituted Syt2-sufficient MC-deficient *W<sup>sh</sup>/W<sup>sh</sup>* mice with BMMCs from *Syt2*<sup>-/-</sup> and *Syt2*<sup>+/+</sup> mice. In histological analysis performed 6 weeks after reconstitution, we identified 101 ± 11 and 98 ± 9 (mean ± S.E.; *n* = 4) MCs per mm<sup>2</sup> of dermis at the site of injection in *W<sup>sh</sup>/W<sup>sh</sup>* mice that received *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> BMMCs, respectively. As shown in Fig. 2, MC-deficient animals failed to mount a response to the antigen challenge. This reaction was rescued by intradermic reconstitution with *Syt2*<sup>+/+</sup> BMMCs. Reconstitution with *Syt2*<sup>-/-</sup> BMMCs provided only a partial (about one-third) rescue compared with *Syt2*<sup>+/+</sup> BMMCs. Pharmacologic interventions have determined that PCA is highly dependent on histamine. Given that this vasoactive amine is stored in MC secretory granules and



**FIGURE 2. Syt2 deficiency impairs the response in passive cutaneous anaphylaxis.** Ears of MC-deficient *W<sup>sh</sup>/W<sup>sh</sup>* mice reconstituted intradermally with *Syt2*<sup>+/+</sup> or *Syt2*<sup>-/-</sup> BMMCs were sensitized with anti-DNP IgE (experimental ear) or polyclonal IgE (control ear). After intravenous challenge with DNP-HSA in Evans Blue, the amount of extravasated dye was measured as absorbance at 610 nm. Nonreconstituted MC-deficient animals failed to respond, and there was a marked difference between mice reconstituted with *Syt2*<sup>-/-</sup> and *Syt2*<sup>+/+</sup> BMMCs. (Error bars represent S.E.; *n* = 9; \*, *p* < 0.01.)


released during degranulation, and that the presence of a Ca<sup>2+</sup>-binding exocytic Syt defines an exocytic event as regulated, we postulated that the lack of Syt2 was negatively affecting MC-regulated exocytosis.

**Syt2 Deficiency Does Not Affect MC Numbers, Differentiation, Structure, or Storage of Granule Contents**—To rule out the possibility that the defective response to PCA was due to an unexpected effect of the absence of Syt2 on some aspect of MC development, we examined MC structure and differentiation in *Syt2*<sup>-/-</sup> mice. We found no difference in the MC density in skin (Fig. 3A and Table 1), peritoneal fluid (Fig. 3B and Table 1), tongue, trachea, stomach, or jejunum (not shown) between *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice. EM images of peritoneal MCs from animals of both genotypes were indistinguishable (Fig. 3C) and unbiased stereological analysis to measure the size and surface complexity of the cells and the number, size, and density of their granules showed no difference (Table 1). We also did not find a difference in the rate of differentiation of bone marrow cells into BMMCs in SCF and IL-3-enriched medium (Table 1) or in the surface density of immunoreactivity against cKit/CD117 and FcεRIα in BMMCs after 6 weeks in culture (Fig. 3D). Morphometric analysis of electron micrographs of *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> BMMCs also failed to uncover a difference (Fig. 3E and Table 1). As part of the secretion assays described below we found almost identical amounts of total cellular histamine (Table 1) and β-hexosaminidase activity (not shown) in unstimulated *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> BMMCs.

Based on these results, we concluded that the lack of Syt2 did not affect the proliferation, migration, and maturation of MCs, the morphology of these cells and of their secretory granules, the expression of receptors important for their maturation and stimulation, and the storage of preformed inflammatory mediators in their secretory granules. Thus, none of these factors explained the defective acute allergic cutaneous response described in Fig. 2.

**Syt2 Selectively Controls Regulated Exocytosis in MCs**—Other possibilities that we needed to test were that the deficient PCA response was part of a more extensive defect affecting all forms of MC secretion and/or the activation of MCs. We studied the functional consequences of the absence of Syt2 in the three main MC secretory effector responses: regulated exocy-





**FIGURE 3. *Syt2* deficiency does not alter MC development, migration into tissues, or morphology.** Representative images of samples obtained from P16 *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice are shown. An in-depth morphometric analysis can be found in Table 1. *A*, fluorescent microscopy of ear sections (bar, 50  $\mu$ m). MCs were labeled with FITC-avidin (green) and cell nuclei with Hoechst (blue). Background tissue was visualized as autofluorescence in the red channel. *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice had similar densities of MCs in the dermis of their ears. *B*, cytopins of peritoneal lavages stained with Wright-Giemsa (bar, 100  $\mu$ m). Insets depict higher power magnifications of representative MCs (bar, 5  $\mu$ m). *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice had similar numbers of MCs with similar gross morphology in their peritoneal cavities. *C*, transmission EM of peritoneal MCs (bar, 1  $\mu$ m). MCs from *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice had similar size and surface

**TABLE 1**

**Quantitation, morphometry, and cellular contents of studied MCs**

Values obtained from four animals of each genotype are expressed as mean  $\pm$  S.E.  $V_v$  denotes granule volume fraction,  $S_v$ , granule surface density, and  $A$ , cell profile area.

	<i>Syt2</i> <sup>+/+</sup>	<i>Syt2</i> <sup>-/-</sup>
<b>Dermal MCs<sup>a</sup></b>		
10 <sup>6</sup> cells/m <sup>2</sup>	183 $\pm$ 15	182 $\pm$ 12
<b>Peritoneal MCs<sup>b</sup></b>		
%	9.7 $\pm$ 1.7	9.3 $\pm$ 1.1
10 <sup>6</sup> cells/liter	180 $\pm$ 13	174 $\pm$ 16
<b>Peritoneal MCs<sup>c</sup></b>		
$V_v$	0.25 $\pm$ 0.02	0.26 $\pm$ 0.02
$S_v$ , 10 <sup>-6</sup> m <sup>-1</sup>	22.89 $\pm$ 1.71	21.82 $\pm$ 2.85
$A$ , 10 <sup>-12</sup> m <sup>2</sup>	33.82 $\pm$ 2.97	32.76 $\pm$ 0.78
<b>BMMCs in culture<sup>d</sup></b>		
2 weeks, %	17.2 $\pm$ 3.1	19.1 $\pm$ 3.9
4 weeks, %	89.1 $\pm$ 4.4	86.2 $\pm$ 5.4
6 weeks, %	97.5 $\pm$ 1.2	97.1 $\pm$ 1.4
<b>BMMCs (6 w)<sup>e</sup></b>		
$V_v$	0.41 $\pm$ 0.04	0.39 $\pm$ 0.03
$S_v$ , 10 <sup>-6</sup> m <sup>-1</sup>	20.77 $\pm$ 2.01	20.46 $\pm$ 1.14
$A$ , 10 <sup>-12</sup> m <sup>2</sup>	43.11 $\pm$ 2.88	48.58 $\pm$ 2.78
<b>BMMCs histamine<sup>e</sup></b>		
10 <sup>-3</sup> g/liter	0.93 $\pm$ 0.11	0.97 $\pm$ 0.09

<sup>a</sup> FITC-avidin<sup>+</sup> cells with a Hoechst<sup>+</sup> nuclear profile per area of dermis in random sections of ear (10 samples/animal).

<sup>b</sup> Calculated from Neubauer chamber counts and Wright-Giemsa staining of cytopins of peritoneal lavages (3 samples/animal).

<sup>c</sup> Stereological analysis of randomly acquired EM images from peritoneal MCs and BMMCs after 6 weeks in culture (10 cell profiles/sample, 4 samples/animal).


<sup>d</sup> Percent of Kit<sup>+</sup>/FcεRIα<sup>+</sup> double positive cells in bone marrow cultures in medium enriched with SCF and IL-3 assessed by flow cytometry (1 sample/animal/time point).

<sup>e</sup> Total histamine concentration in lysates of 10<sup>6</sup> BMMCs measured by ELISA (1 sample/animal).


tosis, constitutive exocytosis, and nonexocytic secretion (6). To simulate the conditions used in our PCA model, we used FcεRI cross-linking to stimulate BMMCs from *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice. After incubating the cells with anti-DNP IgE, we stimulated them by applying DNP-HSA. Because excess of polyvalent antigen can interfere with FcεRI cross-linking, we used the antigen to cell ratio that induced the maximum secretory response in our system (10<sup>6</sup> BMMCs in 1 ml of DNP-HSA at 100 ng/ml, Fig. 4A). To assess exocytosed secretory granule contents, we measured the enzymatic activity of  $\beta$ -hexosaminidase (expressed as a fraction of total cellular content; Fig. 4, A and B) and the amount of histamine (expressed in absolute values, Fig. 4C) in the cell supernatants before and after stimulation. In both cases we found that *Syt2*<sup>-/-</sup> cells showed only about a third of the response found in *Syt2*<sup>+/+</sup> cells. We next measured the release of cytokines under transcriptional control and secreted via constitutive exocytosis, and found no difference in the total amount released (TNF- $\alpha$ , Fig. 5A) or in the time course of this response (IL-4, Fig. 5B). We did not find any difference in the release of products that do not depend on exocytosis for their secretion such as PGD<sub>2</sub> and LTC<sub>4</sub> (Fig. 5, C and D).

The normal secretion of cytokines and lipid mediators, together with the normal surface expression of FcεRIα (Fig.

complexity, and similar number, size, and density of electron-dense granules. *D*, flow cytometry of BMMCs. After 6 weeks in medium supplemented with SCF and IL-3, BMMCs from *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> mice had the same proportion of Kit<sup>+</sup>/FcεRIα<sup>+</sup> cells (% in brackets), and similar surface expression of both receptors (gray lines near both axes represent mean  $\pm$  S.D. of fluorescence intensity). *E*, transmission EM of BMMCs (bar, 1  $\mu$ m). *Syt2*<sup>+/+</sup> and *Syt2*<sup>-/-</sup> BMMCs were indistinguishable.



**FIGURE 4. Syt2 deficiency affects MC-regulated exocytosis.** BMMCs from Syt2<sup>+/+</sup> and Syt2<sup>-/-</sup> mice were incubated with anti-DNP IgE and then exposed to DNP-HSA. Secreted products were measured in supernatants before and 1 h after stimulation. Total β-hexosaminidase enzymatic activity was also measured in cell lysates. *A*, secretion of β-hexosaminidase with different doses of DNP-HSA. Values are expressed as the difference in enzymatic activity in supernatants between stimulated and unstimulated cells in percent of total activity in cell lysates. The maximal response and greatest difference were found at 100 ng/ml DNP-HSA ( $n = 3$ ). This concentration was used in all subsequent experiments. *B*, secretion of β-hexosaminidase at 100 ng/ml DNP-HSA ( $n = 8$ ). *C*, histamine in supernatants before (open bars) and after (black bars) challenge ( $n = 5$ ). Release of products stored in MC secretory granules and secreted via regulated exocytosis was significantly decreased in Syt2<sup>-/-</sup> BMMCs. (Error bars represent S.E.; \*,  $p < 0.01$ .)



**FIGURE 5. Syt2 deficiency does not affect other MC secretory mechanisms.** Secreted products were measured in supernatants of BMMCs from Syt2<sup>+/+</sup> and Syt2<sup>-/-</sup> mice incubated with anti-DNP IgE before and at different time points after addition of DNP-HSA. *A*, TNF-α before (open bars) and after (6 h, black bars) challenge ( $n = 5$ ; color legend applies also to *C* and *D*). *B*, time course of IL-4 secretion ( $n = 3$  per time point). *C*, PGD<sub>2</sub> and *D*, LTC<sub>4</sub> 30 min after challenge ( $n = 4$  for both). Secretion dependent on constitutive exocytosis or independent of exocytosis was not affected in Syt2<sup>-/-</sup> BMMCs. (Error bars represent S.E.)

3D), point to an intact IgE-dependent stimulation mechanism in MCs lacking Syt2, and excludes a defect in this pathway as an explanation for our findings. The presence of an abnormal and selective defect in degranulation confirms that, like in neurons and neuroendocrine cells, the presence of a Ca<sup>2+</sup>-binding Syt defines an exocytic step as a regulated event (7). Our finding that Syt2 discriminates between the secretory compartment containing both β-hexosaminidase and histamine from that containing cytokines is very similar to the findings on VAMP-8 in MCs (27). Another study suggested that VAMP-8 may further discriminate between subpopulations of granules released by regulated exocytosis, as it may control the release of serotonin, cathepsin-D, and β-hexosaminidase but not of histamine (28). Because we found a similar defect in the secretion of β-hexosaminidase and histamine (Fig. 4, *B* and *C*), we postulate that there may be only a single secretory granule population that contains both mediators or that Syt2 controls the exocytosis of the two granule subpopulations.

In nonexcitable cells, another Syt that regulates exocytic events is the high affinity Ca<sup>2+</sup>-binding Syt7 (29), an ubiquitously expressed protein that associates with lysosomal compartments. Although its function in MCs is not known, it is a good candidate to explain the residual exocytic response seen in Syt2<sup>-/-</sup> MCs. Similar functional redundancy can explain why the inhibition of VAMP-7, VAMP-8, and Stx-4 with neutralizing antibodies does not entirely inhibit the release of histamine from MCs compared with the complete suppression obtained with anti-SNAP-23 antibodies (30). Finally, we found no structural or functional difference between Syt2<sup>+/+</sup> and Syt2<sup>+/-</sup> MCs (not shown), so there is no phenotypic haploinsufficiency, similar to our findings in synapses and neuromuscular junctions (16, 17), but different to what we have observed in airway mucous cells (31).

**Syt2 Deficiency Does Not Lead to Increased Spontaneous Degranulation in MCs**—In neurons, Syt2 plays a double role: it is required for the fast synchronized component of the evoked exocytic release of synaptic vesicles, and it also suppresses the slow nonsynchronized component of this process and the spontaneous exocytic events that occur in the absence of stimuli (16, 17). As shown in Fig. 4C, we did not find a difference in the baseline concentration of histamine in the supernatants of Syt2<sup>+/+</sup> and Syt2<sup>-/-</sup> BMMCs, even when these measurements were repeated over 24 h (results not shown). Also, as described in Table 1, the amount of histamine present in cells of both genotypes was almost identical, so there was no evidence of depletion of internal stores.

Thus, like in neurons, Syt2 in MCs is required for an effective regulated exocytic response, but unlike in neurons, its absence does not produce an increase in spontaneous fusion events resulting in depletion of stored products. An explanation for this difference may be the nature of the membrane fusion machinery in these different cells. Neurotransmission takes place within milliseconds after an action potential induces influx of Ca<sup>2+</sup>. In neurons, secretory vesicles are docked at active zones with VAMP-2, SNAP-25, and Syntaxin-1 forming a partially coiled SNARE complex. The cytoplasmic protein complexin “clamps” the complex in this state and prevents complete coiling and membrane fusion. At low [Ca<sup>2+</sup>]<sub>i</sub>, Syt pro-

motes this action of complexin, but as  $[Ca^{2+}]_i$  rises, Syt displaces complexin and actively promotes the “zippering” of the quadruple helix, driving membrane fusion (32). In MCs, regulated exocytosis takes place over minutes and depends on different complexins, v- and t-SNAREs. Perhaps because there is no need for an immediate coupling of  $Ca^{2+}$  entry with exocytosis, the “clamping” effect of Syt2 is not required in MCs, and that may be a consequence of a different interaction with complexin or with the SNARE complex. An alternative explanation is that another Syt isoform plays this negative role in MC exocytosis.


**Syt2 Deficiency Does Not Alter the Stimulated Rise of  $[Ca^{2+}]_i$  in MCs**—In neurons and muscle cells, some voltage-gated  $Ca^{2+}$  channels physically interact with the exocytic proteins Syntaxin, SNAP-25, and Syt. These interactions help localize synaptic vesicles to the active zone and alter the permeability to  $Ca^{2+}$  of these channels (33). Furthermore, some Syt channel complexes are the target of autoantibodies in Lambert-Eaton myasthenic syndrome (34). Even though there is no reported physical or functional interaction between a Syt and the inositol trisphosphate receptor, STIM (stromal interaction molecule), or components of the  $Ca^{2+}$  release activated  $Ca^{2+}$  channel such as Orai1/CRACM1, it was important to confirm that the defective exocytic response we found in *Syt2*<sup>−/−</sup> MCs was not due to an impairment of store-operated  $Ca^{2+}$  entry in this nonexcitable cell (35).

In purified peritoneal MCs passively sensitized with specific IgE, we found no difference in the increase of  $[Ca^{2+}]_i$  ( $\Delta[Ca^{2+}]_i$ ) after challenge by exposure to the cognate antigen (Fig. 6, A and B). Thus, it is a deficiency in a  $Ca^{2+}$  sensor, and not in upstream  $Ca^{2+}$  signaling that explains the degranulation defect in *Syt2*<sup>−/−</sup> MCs.

**Syt2 Deficiency Does Not Impair Secretory Granule Exocytic Competence in MCs**—Another possibility we explored was to determine whether the effects of lack of Syt2 in MCs were indirect, affecting exocytosis by altering the competence of the core exocytic machinery. For example, the deletion of VAMP-2 (36) or SNAP-25 (37) produces a defect in neurotransmitter release that cannot be overcome by any stimulus because a core component of the neuronal exocytic machinery is absent.

Single peritoneal MCs from *Syt2*<sup>+/+</sup> and *Syt2*<sup>−/−</sup> mice were strongly stimulated by intracellular dialysis with GTP $\gamma$ S and a persistent high  $[Ca^{2+}]_i$  (25), while measuring plasma membrane capacitance ( $C_m$ ). We found no difference in plasma membrane capacitance gain ( $\Delta C_m$ ), demonstrating that the total amount of granule membrane incorporated into the plasma membrane via exocytosis was the same, and therefore that the membrane fusion machinery was intact (Fig. 6, C and D). Similar to our findings, application of an intervention that induces neuronal exocytosis via a mechanism independent of Syts (hypertonic sucrose) to neurons deficient in Syt1 (14), Syt2 (16), or Syt9 (15) elicited similar levels of vesicle fusion when compared with wild-type controls.

**Summary**—We found that Syt2 controls exclusively regulated exocytosis in MCs *in vitro* and *in vivo* and not constitutive exocytosis or nonexocytic secretion. We also found that this  $Ca^{2+}$  sensor has no “clamping” activity on spontaneous exocytosis in this nonexcitable cell. Although the



**FIGURE 6. Syt2 deficiency does not affect  $[Ca^{2+}]_i$  transients or MC exocytic competence.** A, representative  $[Ca^{2+}]_i$  traces of isolated peritoneal MCs incubated with anti-DNP IgE and stimulated by addition of DNP-HSA (arrows). Gray lines represent the mean baseline and maximal  $[Ca^{2+}]_i$ , used to calculate  $\Delta[Ca^{2+}]_i$ . B, average  $\Delta[Ca^{2+}]_i$  showed no difference between the two genotypes ( $n = 9$ ). C, representative  $C_m$  traces (upper panels) measured in peritoneal MCs dialyzed with 5  $\mu M$  GTP $\gamma$ S via the patch pipette. The  $[Ca^{2+}]_i$  in both cells was buffered to 700 nM (lower panels). D, average  $\Delta C_m$  demonstrated that degranulation can be induced in *Syt2*<sup>−/−</sup> MCs under these conditions ( $n = 8$ ; error bars represent S.E.).

defect in Syt2-deficient mice is profound, it is not absolute, and it would be interesting to explore if another Syt such as Syt7 could explain this residual exocytic activity. We also found that the PCA reaction is highly dependent on MC-regulated exocytosis, suggesting that it may be possible to control the acute phase of the allergic response by manipulating this exocytic step.



## REFERENCES

1. Yu, M., Tsai, M., Tam, S. Y., Jones, C., Zehnder, J., and Galli, S. J. (2006) *J. Clin. Invest.* **116**, 1633–1641
2. McNeil, H. P., Shin, K., Campbell, I. K., Wicks, I. P., Adachi, R., Lee, D. M., and Stevens, R. L. (2008) *Arthritis Rheum.* **58**, 2338–2346
3. Lee, D. M., Friend, D. S., Gurish, M. F., Benoist, C., Mathis, D., and Brenner, M. B. (2002) *Science* **297**, 1689–1692
4. Thakurdas, S. M., Melicoff, E., Sansores-Garcia, L., Moreira, D. C., Petrova, Y., Stevens, R. L., and Adachi, R. (2007) *J. Biol. Chem.* **282**, 20809–20815
5. Malaviya, R., Ikeda, T., Ross, E., and Abraham, S. N. (1996) *Nature* **381**, 77–80
6. Adachi, R., Nigam, R., and Dickey, B. F. (2003) in *Mast Cell Exocytosis in Airway Inflammation, Therapeutic Targets in Airway Inflammation* (Eissa, N. T., and Huston, D. P., eds) pp. 327–348, Marcel Dekker, New York
7. Verhage, M., and Toonen, R. F. (2007) *Curr. Opin. Cell Biol.* **19**, 402–408
8. Loe, D. W., Almquist, K. C., Deeley, R. G., and Cole, S. P. (1996) *J. Biol. Chem.* **271**, 9675–9682
9. Wong, A., Cook, M. N., Foley, J. J., Sarau, H. M., Marshall, P., and Hwang, S. M. (1991) *Biochemistry* **30**, 9346–9354
10. Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., and Kalogeromitros, D. (2007) *Immunol. Rev.* **217**, 65–78
11. Turner, H., and Kinet, J. P. (1999) *Nature* **402**, B24–B30
12. Jahn, R., Lang, T., and Südhof, T. C. (2003) *Cell* **112**, 519–533
13. Chapman, E. R. (2008) *Annu. Rev. Biochem.* **77**, 615–641
14. Geppert, M., Goda, Y., Hammer, R. E., Li, C., Rosahl, T. W., Stevens, C. F., and Südhof, T. C. (1994) *Cell* **79**, 717–727
15. Xu, J., Mashimo, T., and Südhof, T. C. (2007) *Neuron* **54**, 567–581
16. Sun, J., Pang, Z. P., Qin, D., Fahim, A. T., Adachi, R., and Südhof, T. C. (2007) *Nature* **450**, 676–682
17. Pang, Z. P., Melicoff, E., Padgett, D., Liu, Y., Teich, A. F., Dickey, B. F., Lin, W., Adachi, R., and Südhof, T. C. (2006) *J. Neurosci.* **26**, 13493–13504
18. Baram, D., Adachi, R., Medalia, O., Tuvim, M., Dickey, B. F., Mekori, Y. A., and Sagi-Eisenberg, R. (1999) *J. Exp. Med.* **189**, 1649–1658
19. Wolters, P. J., Mallen-St Clair, J., Lewis, C. C., Villalta, S. A., Baluk, P., Erle, D. J., and Caughey, G. H. (2005) *Clin. Exp. Allergy* **35**, 82–88
20. Peterson, D. A. (1999) *Methods* **18**, 493–507
21. Zhou, Z. Y., Wan, Q. F., Thakur, P., and Heidelberger, R. (2006) *J. Neurophysiol.* **96**, 2539–2548
22. Heidelberger, R., and Matthews, G. (1992) *J. Physiol.* **447**, 235–256
23. Riedel, D., Antonin, W., Fernandez-Chacon, R., Alvarez, de, Toledo, G., Jo, T., Geppert, M., Valentijn, J. A., Valentijn, K., Jamieson, J. D., Südhof, T. C., and Jahn, R. (2002) *Mol. Cell. Biol.* **22**, 6487–6497
24. Neher, E. (1988) *J. Physiol.* **395**, 193–214
25. Fernandez, J. M., Neher, E., and Gomperts, B. D. (1984) *Nature* **312**, 453–455
26. Inagaki, N., Goto, S., Nagai, H., and Koda, A. (1986) *Int. Arch. Allergy Appl. Immunol.* **81**, 58–62
27. Tiwari, N., Wang, C. C., Brochetta, C., Ke, G., Vita, F., Qi, Z., Rivera, J., Soranzo, M. R., Zabucchi, G., Hong, W., and Blank, U. (2008) *Blood* **111**, 3665–3674
28. Puri, N., and Roche, P. A. (2008) *Proc. Natl. Acad. Sci. U.S.A.* **105**, 2580–2585
29. Chakrabarti, S., Kobayashi, K. S., Flavell, R. A., Marks, C. B., Miyake, K., Liston, D. R., Fowler, K. T., Gorelick, F. S., and Andrews, N. W. (2003) *J. Cell Biol.* **162**, 543–549
30. Sander, L. E., Frank, S. P., Bolat, S., Blank, U., Galli, T., Bigalke, H., Bischoff, S. C., and Lorentz, A. (2008) *Eur. J. Immunol.* **38**, 855–863
31. Tuvim, M. J., Mospan, A. R., Burns, K. A., Chua, M., Mohler, P. J., Melicoff, E., Adachi, R., Ammar-Aouchiche, Z., Davis, C. W., and Dickey, B. F. (2009) *J. Biol. Chem.* **284**, 9781–9787
32. Carr, C. M., and Munson, M. (2007) *EMBO Rep.* **8**, 834–838
33. Catterall, W. A. (1999) *Ann. N. Y. Acad. Sci.* **868**, 144–159
34. Leveque, C., Hoshino, T., David, P., Shoji-Kasai, Y., Leys, K., Omori, A., Lang, B., el, Far, O., Sato, K., and Martin-Moutot, N. (1992) *Proc. Natl. Acad. Sci. U.S.A.* **89**, 3625–3629
35. Vig, M., and Kinet, J. P. (2007) *Cell Calcium* **42**, 157–162
36. Schoch, S., Deak, F., Königstorfer, A., Mozhayeva, M., Sara, Y., Südhof, T. C., and Kavalali, E. T. (2001) *Science* **294**, 1117–1122
37. Washbourne, P., Thompson, P. M., Carta, M., Costa, E. T., Mathews, J. R., Lopez-Bendito, G., Molnár, Z., Becher, M. W., Valenzuela, C. F., Partridge, L. D., and Wilson, M. C. (2002) *Nat. Neurosci.* **5**, 19–26